Recent News

• 09.03.2025 - 60 Degrees Pharmaceuticals Live Webcast Link and New Date for Presentation at H.C. Wainwright 27th Annual Global Investment Conference
• 09.03.2025 - 60 Degrees Pharmaceuticals Live Webcast Link and New Date for Presentation at H.C. Wainwright 27th Annual Global Investment Conference
• 08.21.2025 - 60 Degrees Pharmaceuticals to Present at H.C. Wainwright 27th Annual Global Investment Conference
• 08.21.2025 - 60 Degrees Pharmaceuticals to Present at H.C. Wainwright 27th Annual Global Investment Conference
• 08.19.2025 - 60 Degrees Pharmaceuticals Selects Icahn School of Medicine at Mount Sinai as Central Clinical Trial Site for Phase II Study to Evaluate Tafenoquine for Chronic Babesiosis
• 08.19.2025 - 60 Degrees Pharmaceuticals Selects Icahn School of Medicine at Mount Sinai as Central Clinical Trial Site for Phase II Study to Evaluate Tafenoquine for Chronic Babesiosis
• 08.13.2025 - 60 Degrees Pharmaceuticals Announces Second Quarter 2025 Results
• 08.13.2025 - 60 Degrees Pharmaceuticals Announces Second Quarter 2025 Results
• 07.17.2025 - 60 Degrees Pharmaceuticals and Tulane University Sign Research Agreement to Study Tafenoquine Against Lyme and Bartonella Bacteria

Recent Filings

• 09.02.2025 - DEFR14A Revised definitive proxy soliciting materials
• 08.27.2025 - DEF 14A Other definitive proxy statements
• 08.15.2025 - PRE 14A Other preliminary proxy statements
• 08.14.2025 - 4 Statement of changes in beneficial ownership of securities
• 08.14.2025 - 3 Initial statement of beneficial ownership of securities
• 08.14.2025 - 4 Statement of changes in beneficial ownership of securities
• 08.13.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 07.22.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 07.18.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 07.18.2025 - 8-K Current report